Castle Biosciences, Inc. (CSTL) Stock Score, Valuation & Financial Research
Castle Biosciences, Inc. is in the Healthcare sector and Medical - Diagnostics & Research industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 27/100.
Quick answer for CSTL
Castle Biosciences, Inc. currently has a Wall Street Score of 27/100. The stored market price is $35.48. Its financial score is 32/100. Its valuation score is 0/100. The latest WSS change is -0.1 points. These figures are a research snapshot, not a buy or sell recommendation.
What Castle Biosciences, Inc. does
Castle Biosciences, Inc. functions as a commercial-stage diagnostics firm, with its primary objective being the provision of both diagnostic and prognostic testing services, specifically targeting various dermatological cancers. Their flagship product, DecisionDx-Melanoma, represents an advanced multi-gene expression profile (GEP) assay engineered to assess the probability of metastasis in patients afflicted with invasive cutaneous melanoma. In addition to their leading solution, the company has created several other specialized, proprietary tests. Among these is DecisionDx-UM, a GEP test tailored to forecast the risk of metastasis for individuals with uveal melanoma, a less common malignancy of the eye. Another key offering is DecisionDx-SCC, a distinctive 40-gene expression profile test that utilizes a patient's unique tumor biology to predict their specific risk of squamous cell carci
CSTL financial snapshot
- Wall Street Score:
- 27/100
- Current price:
- $35.48
- Market capitalization:
- $1.08B
- Revenue:
- $357.3M
- Net income:
- $-19.4M
- Free cash flow:
- $28.3M
- Cash:
- $62.1M
- Total debt:
- $36.6M
- EPS:
- -0.66
- Financial score:
- 32/100
- Valuation score:
- 0/100
- Revenue score:
- 27/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $28.3M, showing positive cash generation.
- The balance sheet shows $62.1M of cash versus $36.6M of total debt, leaving more cash than debt.
- The latest Wall Street Score change is -0.1 points: CSTL decreased 0.1 points because some fundamentals weakened.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 32/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-17.
How to research CSTL
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.